Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha (Lead / Corresponding author), Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purdie, Dave Purnell, Sarah E. Pinder, Ian O. Ellis, Andrew H. S. Lee
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases'. Together they form a unique fingerprint.